Clinical Trails to Study Cardiovascular outcome in overweight/obesity
We are currently enrolling for:
Cardiovascular Clinical Trials
Do you have poor circulation? Have you ever had a heart attack or stroke? Research has shown that treatment with semaglutide may reduce the risk of stroke or heart attack in people with type 2 diabetes. In this study called SELECT, we will check to see if semaglutide can reduce the risk of cardiovascular events in people with obesity. You will receive Semaglutide or placebo during this trial. Your health is very important to us and will be monitored throughout the study. Participating in a clinical trial can improve future treatment options for you and other people with cardiovascular diseases. Learn more about our clinical study for cardio health in Philadelphia.
SELECT Study Qualifications
- Age 45 Years old or more
- You are living with obesity
- You have a history of peripheral arterial disease, heart attack or stroke
- You do not have Type 1 or Type 2 diabetes
Paid Research Studies
9501 Roosevelt Blvd
Philadelphia, PA 19114
Participants in our SELECT clinical trial receive study related medication and medical care at no cost. Participants may also be compensated for their time and travel. You must be able to travel to our offices. You can speak with our organization's intake specialist for more information on this topic.
What is Semaglutide?
Semaglutide is a medicine which is similar to a natural hormone called glucagon-like peptide-1 (GLP-1). GLP-1 is produced in the body after eating a meal. Medicines belonging to the GLP-1 class are normally given as an injection and some are already available on the market to treat diseases like type 2 diabetes and obesity.